ArticleStem cell research & therapy2013
Among mesenchymal stem cells: for the best therapy after ischemic stroke.
Article in Stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 11 citations in OpenAlex.
- Preconditioning of bone marrow-derived mesenchymal stromal cells by tetramethylpyrazine enhances cell migration and improves functional recovery after focal cerebral ischemia in rats.Stem cell research & therapy · 2017Article
- Qualitative and quantitative analysis of MR imaging findings in patients with middle cerebral artery stroke implanted with mesenchymal stem cells.AJNR. American journal of neuroradiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to the several advantages that they have over other cells, mesenchymal stem cells are among the most promising tools in stem cell therapy after ischemic stroke. Mesenchymal stem cells can be obtained from various sources. Therefore, a wide range of careful comparative studies of these cells is required, from the preclinical stage (in vitro and in vivo) to the clinical stage, in order to develop the best therapy with the most appropriate cell type. An in vivo study in this issue of Stem Cell Research & Therapy compares the therapeutic potential of two cell types, obtained from bone marrow and adipose tissue, in a rodent stroke model. This commentary discusses the significance of comparative studies of mesenchymal stem cells, including the related article in translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.